When Donald Trump is back in the saddle, one thing is certain: Tariff wars. Yes, China will be the biggest target. But for all those who think India will be unaffected, just do a Google search for “Trump on high import duty on Harley Davidson bikes”. A further indication came just a few days ago when he mentioned Brazil and India in the same breath, saying that the two countries were imposing high tariffs and should expect consequences. While it may not become a major issue, there may well be some retaliation. Or the threat of retaliation could be used as a tool to get India to change its stance on some global issue. Or as a quid pro quo: For instance, a push for lower duties on EVs, especially cars – a move that could help Trump’s biggest backer Elon Musk and his Tesla. But one sector which would be relatively safe could be pharma, and there are reasons for it. And mind you, we are using the word “ relatively”.Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardized scores. SR+ Reports is a complimentary offering to ETPrime members.
